Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BENEMID vs PROBENECID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of renal tubular secretion of organic acids (urate, penicillin, other drugs), enhancing urate excretion and reducing serum uric acid levels. Also inhibits renal transport of weak organic acids.
Inhibits renal tubular reabsorption of uric acid, increasing its excretion and lowering serum urate levels. Also inhibits renal tubular secretion of weak acids (e.g., penicillins, cephalosporins).
Treatment of hyperuricemia associated with gout and gouty arthritis,Adjunctive therapy for penicillin and cephalosporin antibiotics to prolong their serum half-life
FDA: Treatment of hyperuricemia associated with gout (prophylaxis and chronic management), adjunct to penicillin or cephalosporin therapy to elevate and prolong antibiotic levels.,Off-label: Prevention of nephropathy in patients with hyperuricemia, adjunct to antiviral agents (e.g., cidofovir) to reduce nephrotoxicity.
250 mg orally twice daily for 1 week, then 500 mg orally twice daily; maximum 2 g/day.
Oral: 250 mg twice daily for 1 week, then 500 mg twice daily; for gout prophylaxis, initial 250 mg twice daily for 3-4 weeks then increase to 500 mg twice daily; for hyperuricemia secondary to thiazide diuretics, 250 mg twice daily.
Terminal elimination half-life 6-12 hours in adults; prolonged to 12-24 hours in renal impairment or elderly; clinically significant for twice-daily dosing
Terminal elimination half-life is approximately 6-12 hours in adults with normal renal function; may be prolonged in renal impairment or older adults.
Hepatic metabolism via oxidation and glucuronidation; minimal CYP450 involvement.
Primarily hepatic via oxidation and glucuronidation; minor renal metabolism.
Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%)
Renal excretion of unchanged drug and metabolites; ~77% of dose recovered in urine within 48 hours (50% as glucuronide conjugates, 27% as unchanged probenecid); ~11% excreted in feces via biliary elimination.
Approximately 85-95% bound primarily to albumin
Approximately 75-95% bound to plasma albumin.
0.15-0.30 L/kg; indicates limited extravascular distribution, consistent with high protein binding and renal elimination
Apparent volume of distribution is about 9 L (approximately 0.13 L/kg in adults); indicates limited extravascular distribution, primarily confined to plasma and extracellular fluid.
Oral: >90%
Oral bioavailability is nearly complete (>90%) with peak plasma concentrations achieved within 2-4 hours.
Cr Cl <50 m L/min: avoid use; Cr Cl 50-90 m L/min: reduce dose by 50%.
GFR 10-50 m L/min: 250 mg once daily or 500 mg every 12-24 hours; GFR <10 m L/min: avoid use; anuria: contraindicated.
No specific guidelines; use with caution in severe hepatic impairment.
No specific adjustment recommended; use caution in severe hepatic impairment.
Not recommended for children under 2 years. For older children: 25 mg/kg/day divided every 6 hours, up to 40 mg/kg/day maximum 2 g/day.
For gout or hyperuricemia (children >2 years): 25 mg/kg/day (max 2 g/day) divided every 6-8 hours; as adjunct to penicillin/cephalosporin: 25 mg/kg/day (max 2 g/day) divided every 8 hours for infants >3 months and children; neonates: dose not established.
Start at low end of dosing range (250 mg twice daily); monitor renal function and urate levels.
Start at lowest dose (250 mg once daily) due to age-related renal impairment; monitor renal function regularly; avoid if GFR <30 m L/min.
No FDA black box warning.
None.
Risk of acute gouty arthritis upon initiation; use NSAIDs or colchicine prophylactically. Use with caution in patients with peptic ulcer disease, renal impairment (Cr Cl <50 m L/min), or history of uric acid calculi. May cause aplastic anemia and other blood dyscrasias. Avoid use during acute gout attack.
Use with caution in patients with peptic ulcer disease.,May worsen acute gouty arthritis; prophylactic colchicine or NSAIDs recommended during initiation.,Risk of uric acid stone formation; ensure adequate hydration and alkalinize urine if needed.,Avoid use in patients with blood dyscrasias or bone marrow depression.,May interfere with urine glucose and ketone tests.
Known hypersensitivity to probenecid; use with methotrexate or other nephrotoxic agents; severe renal impairment (Cr Cl <50 m L/min); blood dyscrasias; uric acid kidney stones; children under 2 years of age.
Hypersensitivity to probenecid or any component.,Severe renal impairment (Cr Cl <50 m L/min) or anuria.,History of uric acid kidney stones.,Concomitant use with methotrexate (increases methotrexate toxicity).,Use during acute gouty attack (unless already on therapy).
Avoid high doses of aspirin or salicylate-containing foods. Maintain adequate fluid intake. No specific food restrictions but alcohol may increase serum uric acid and reduce efficacy. Avoid large doses of vitamin C (may acidify urine and increase urate stone risk).
Avoid high-purine foods (organ meats, sardines, anchovies, shellfish, red meat) as they increase uric acid levels. Limit alcohol, especially beer and spirits, which increase uric acid. Maintain high fluid intake (water, citrus juices) to promote urine flow and prevent stones. Avoid cranberry juice as it may acidify urine.
FDA Pregnancy Category D for second and third trimesters due to risk of neonatal hemolysis and jaundice from sulfonamide component; first trimester use associated with possible neural tube defects based on animal data and limited human reports.
Probenecid is FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies exist. Use only if clearly needed. First trimester: No known teratogenic effects. Second and third trimesters: No specific fetal risks documented; avoid near term due to potential for neonatal hyperbilirubinemia (displaces bilirubin from albumin).
Small amounts of probenecid and sulfonamide excreted into breast milk; M/P ratio not established. Potential for hemolysis in G6PD-deficient infants, jaundice, and kernicterus in premature infants. Contraindicated in nursing mothers due to sulfonamide component.
Probenecid is excreted into breast milk in low concentrations; M/P ratio not available. Consider benefits of breastfeeding versus potential risk of adverse effects in infant (e.g., rash, gastrointestinal effects). Use with caution.
Increased renal clearance and volume of distribution in pregnancy may reduce probenecid half-life; dose adjustment based on therapeutic response and serum uric acid levels is recommended. No specific dosing guidelines; clinical judgment advised.
No formal pharmacokinetic studies during pregnancy. Dose adjustment not routinely recommended, but consider decreased efficacy due to increased renal clearance in pregnancy. Monitor clinical response and adjust dose if needed.
BENEMID (probenecid) inhibits renal tubular secretion of penicillins and cephalosporins, increasing their serum levels. Use with caution in patients with G6PD deficiency due to risk of hemolytic anemia. Avoid in patients with blood dyscrasias or peptic ulcer disease. Ensure adequate hydration to prevent urate nephropathy during gout therapy.
Probenecid inhibits renal tubular secretion of uric acid, increasing its excretion; used for chronic gout, not acute attacks. It also reduces renal excretion of penicillins and cephalosporins, so it is used to increase serum levels of these antibiotics. Ensure adequate hydration (at least 2-3 L daily) to prevent urate nephropathy. Avoid in patients with creatinine clearance <50 m L/min, history of uric acid stones, or acute gout attack. Alkalinization of urine (urine p H 6.5-7) reduces stone risk. Monitor serum uric acid, renal function, and CBC. Drug interactions: potentiates toxicity of methotrexate, NSAIDs, thiazides, salicylates (salicylates antagonize uricosuric effect).
Take with food or milk to reduce gastrointestinal upset.,Drink plenty of fluids (at least 2 liters daily) to prevent kidney stones.,Do not take with aspirin or other salicylates as they may reduce effectiveness.,This medication may increase the effects of other drugs like penicillins and methotrexate.,Report any signs of allergic reaction, severe skin rash, or joint pain immediately.
Take probenecid with food or antacids to reduce GI upset.,Drink at least 8-10 glasses of water daily while on this medication.,Do not take aspirin or other salicylates; they can reduce the effect.,This drug may increase bleeding risk if you take blood thinners like warfarin.,Report any signs of allergic reaction, rash, or fever immediately.,Avoid alcohol as it increases uric acid levels.,Tell your doctor before taking other medications, especially antibiotics.,Do not use during an acute gout attack; wait until attack resolves.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Store at room temperature, away from moisture and heat.
No interactions on record
"Edoxaban, a direct factor Xa inhibitor, may inhibit organic anion transporters (OATs) involved in the renal excretion of probenecid, leading to increased probenecid plasma concentrations. Elevated probenecid levels can enhance its uricosuric effect and potentially increase the risk of adverse effects such as gastrointestinal disturbances and hypersensitivity reactions. Clinicians should be aware of this interaction when coadministering these agents, particularly in patients with renal impairment."
"Acemetacin, a nonsteroidal anti-inflammatory drug (NSAID) and prodrug of indomethacin, reduces renal clearance of probenecid by inhibiting tubular secretion and possibly competing for organic anion transporters. This leads to increased plasma concentrations of probenecid, prolonging its half-life and enhancing its uricosuric effect. Clinically, this interaction may result in elevated risk of probenecid toxicity, including gastrointestinal discomfort, rash, or rare blood dyscrasias, while also potentially increasing the anti-inflammatory effects of acemetacin."
"Cilostazol, a phosphodiesterase III inhibitor, can inhibit the renal tubular secretion of probenecid, a uricosuric agent, thereby decreasing its clearance and increasing its serum concentration. This elevation may potentiate the effects and toxicity of probenecid, including an increased risk of uric acid nephropathy and gastrointestinal disturbances. The interaction is of particular concern in patients with renal impairment or those receiving concurrent nephrotoxic drugs."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BENEMID vs PROBENECID, answered by our medical review team.
BENEMID is a Uricosuric Agent that works by Competitive inhibitor of renal tubular secretion of organic acids (urate, penicillin, other drugs), enhancing urate excretion and reducing serum uric acid levels. Also inhibits renal transport of weak organic acids.. PROBENECID is a Uricosuric that works by Inhibits renal tubular reabsorption of uric acid, increasing its excretion and lowering serum urate levels. Also inhibits renal tubular secretion of weak acids (e.g., penicillins, cephalosporins).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BENEMID and PROBENECID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BENEMID is: 250 mg orally twice daily for 1 week, then 500 mg orally twice daily; maximum 2 g/day.. The standard adult dose of PROBENECID is: Oral: 250 mg twice daily for 1 week, then 500 mg twice daily; for gout prophylaxis, initial 250 mg twice daily for 3-4 weeks then increase to 500 mg twice daily; for hyperuricemia secondary to thiazide diuretics, 250 mg twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BENEMID and PROBENECID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BENEMID is classified as Category C. FDA Pregnancy Category D for second and third trimesters due to risk of neonatal hemolysis and jaundice from sulfonamide component; first trimester use associated with possible neu. PROBENECID is classified as Category A/B. Probenecid is FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies exist. Use only if clearly needed. First trimester: No known . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.